| Company Name: |
Daicel Chiral Technologies (China)CO.,LTD
|
| Tel: |
021-50460086-9 15921403865 |
| Email: |
han_yajun@dctc.daicel.com |
| Products Intro: |
Product Name:Edoxaban-D6
CAS:1304701-57-2
Purity:95% HPLC Package:10mg ;25mg;50mg;100mg Remarks:DCTI-A-219
|
| Company Name: |
Clearsynth Canada Inc.
|
| Tel: |
+1.415.685.4395 |
| Email: |
enquiry@clearsynth.com |
| Products Intro: |
Product Name:Edoxaban D6
CAS:1304701-57-2
Remarks:CS-O-11960
|
| Company Name: |
Shanghai Han-Xiang Chemical Co., Ltd.
|
| Tel: |
15971444841 |
| Email: |
amber@biochempartner.com |
| Products Intro: |
Product Name:Edoxaban-d6
CAS:1304701-57-2
Purity:98% HPLC LCMS Package:100G;1KG
|
| Company Name: |
Jinan blalong chemical co. LTD
|
| Tel: |
2710913286@.com |
| Email: |
1513643261@qq.com |
| Products Intro: |
Product Name:Edoxaban-d6
CAS:1304701-57-2
Purity:99% HPLC Package:50G;10G;1G;500MG;100MG
|
|
| | Edoxaban-d6 Basic information |
| Product Name: | Edoxaban-d6 | | Synonyms: | Edoxaban-d6;N-[(1S,2R,4S)-4-[bis(trideuteriomethyl)carbamoyl]-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]-N'-(5-chloropyridin-2-yl)oxamide;[2H6]-Edoxaban;Edoxaban hydrochloride salt;2H6]-Edoxaban hydrochloride salt | | CAS: | 1304701-57-2 | | MF: | C24H30ClN7O4S | | MW: | 548.06 | | EINECS: | | | Product Categories: | | | Mol File: | 1304701-57-2.mol |  |
| | Edoxaban-d6 Chemical Properties |
| Melting point | >205°C (dec.) | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | Chloroform (Slightly), Dichloromethane (Slightly) | | form | Solid | | color | Pale Orange to Pale Red | | Stability: | Hygroscopic |
| | Edoxaban-d6 Usage And Synthesis |
| Description | Edoxaban-d6 is intended for use as an internal standard for the quantification of edoxaban by GC- or LC-MS. Edoxaban is an orally bioavailable and potent inhibitor of factor Xa (Kis = 0.561 and 0.903 nM for free and complexed human factor Xa, respectively). It is >10,000-fold selective for factor Xa over thrombin, FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin, and chymotrypsin. Edoxaban prolongs prothrombin, activated partial thromboplastin, and thrombin clotting times in a concentration-dependent manner ex vivo in human plasma. Oral administration of edoxaban (0.5-12.5 mg/kg) reduces thrombus formation and prolongs prothrombin time in a dose-dependent manner in rat and rabbit models of venous stasis thrombosis. It also reduces thrombus formation in a rat model of platinum wire-induced venous thrombosis. Formulations containing edoxaban have been used to prevent stroke in patients with atrial fibrillation. | | Uses | Edoxaban-d6 is the isotope labelled analog of Edoxaban (E555520); an anticoagulant drug which acts as a direct factor Xa inhibitor. |
| | Edoxaban-d6 Preparation Products And Raw materials |
|